Little Green Pharma has shifted its laboratory testing to the in-house lab of the Therapeutic Goods Administration (TGA) following the contentious publication of a TGA report identifying products which failed a potency audit.
The WA-based firm was one of four suppliers named in the audit whose products were found to have breached TGO93 requirements. The others were Althea, Spectrum Therapeutics and Bedrocan.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
It occurs to me that there may have been a political motive behind the publication of the results. Given that the policy of various government bodies is to disparage cannabis and all things related to the cannabis industry it comes as no surprise that the TGA may wish to make trouble for the industry rather than support the coming raft of changes.